FOLR1 and cancer: FRα is an attractive TAA since about 70% of EOC and breast cancer patients showed measurable immune responses against FRα [169], and, due to its highly restricted distribution and overexpression in EOC, FRα is a suitable candidate for cancer immunotherapy.